KURAに登録されているコンテンツの著作権は、執筆者、出版社（学協会）などが有します。KURAに登録されているコンテンツの利用については、著作権法に規定されている私的使用や引用などの範囲内で行ってください。著作権法に規定されている私的使用や引用などの範囲を超える利用を行う場合には、著作権者の許諾を得てください。ただし、著作権者から著作権等管理事業者（学術著作権協会、日本著作出版権管理システムなど）に権利委託されているコンテンツの利用手続については、各著作権等管理事業者に確認してください。
LETTER TO JMG

A full genome scan for gastric cancer


It is generally accepted that multiple factors play a role in gastric carcinogenesis, including diet, lifestyle, infectious agents such as Helicobacter pylori (H. pylori), and genetic factors as well as gene-environment interactions. Although the continuous decrease in the incidence of gastric cancer in recent decades can be explained by changing lifestyle, diet habits, and reduced H. pylori infection, the fact that some individuals develop gastric cancer while others do not under similar environmental exposures suggests that genetic predisposition plays an important role in the pathogenesis of this disease. In addition, familial clustering of cases of gastric cancer, a higher incidence of the disease among the relatives of patients than among matched controls, and a more common coincidence of the disease in homozygotic than in heterozygotic twins, also supports genetic links with gastric cancer.

In contrast with the vast amount of accumulated information on environmental factors, little is known about the genetic factors linked to gastric cancer. Several studies have reported disease susceptible loci for gastric cancer, based on association analysis of candidate genes involved in DNA repair, detoxification, or the immune system. Studies on familial clustering of gastric cancer revealed germline mutations in CDH1, ATM, and MET. In addition, gastric cancer frequently occurs in families with monogenic diseases such as hereditary non-polyposis colorectal cancer, Li-Fraumeni syndrome, familial adenomatous polyposis, and Peutz-Jeghers syndrome. However, these polymorphisms and/or mutations cannot explain the overall genetic components of gastric cancer.

It is now feasible to screen the entire human genome for genes exerting a major effect on susceptibility to multifactorial diseases. Because gastric cancer, like many complex diseases, exhibits genetic heterogeneity, we carried out a genome-wide linkage study to search for possible susceptibility loci related to gastric cancer, using a non-parametric sibpair method in 170 affected sibpairs from 142 Japanese families. The data we obtained yielded chromosomal regions that are likely to harbour human gastric cancer susceptibility genes.

METHODS

Families

A total of 297 gastric cancer patients, including 170 informative sibpairs, from 142 Japanese families were recruited with the approval of the Ethical Committee of Kyushu University, Fukuoka, Japan. Nine of the families included three affected sibs and two included four affected sibs. The mean age at diagnosis of these 297 patients was 57.0 years and the male to female ratio was 1.69. All participants provided written informed consent. The diagnosis of gastric cancer was confirmed by pathological records and/or by examination of medical records at hospitals where the patients were surgically treated.

Genotyping

Genotyping was carried out as described. Briefly, genomic DNA was extracted from total peripheral blood using QIAamp DNA Blood Mid Kits (Qiagen, Valencia, CA, USA). ABI PRISM Linkage Mapping Set Version 2 (Applied Biosystems, Foster City, CA, USA) was used for amplification of 392 microsatellite markers spanning the entire genome with an average interval of 10 cm. PCR reaction was carried out in a 15 μl volume using reagent concentrations and temperature profiles as recommended by the manufacturer (Applied Biosystems). Amplification of the expected size of double strand DNA was confirmed by agarose gel electrophoresis. The fluorescence labelled PCR products were pooled (10–20 markers/pool) and electrophoresis was carried out using the ABI PRISM model 377 or 3100 DNA sequencer equipped with Genescan software (Applied Biosystems) for

Key points

- We carried out a genome-wide screen to search for regions of the human genome containing gastric cancer susceptibility genes in 170 affected sibpairs from 142 Japanese families, using 392 microsatellite markers spanning the entire genome.
- Non-parametric linkage analysis of the entire data set, using the MAPMAKER/SIBS program, identified four regions, 1p32, 2q33–q35, 11p13–p14, and 21q21, showing evidence for linkage with a multipoint logarithm of odds (LOD) score of ≥1.8 (p≤0.01). The strongest signal was observed on chromosome 2q33–35 (multipoint and two point LOD scores of 1.74 and 1.98, respectively).
- In an analysis of a subgroup with proximal gastric cancer, the signal of linkage to 2q33–q35 increased to multipoint and two point LOD scores of 3.61 and 2.93, respectively. Simulation studies revealed that this finding exceeded that expected by chance (p=0.002). Furthermore, a linkage signal to chromosome 2q33–35 was confirmed by additional markers and the MERLIN program (multipoint LOD scores of 3.38 and 2.66, respectively). Our results suggest the presence of a gastric cancer susceptibility locus on this chromosome.

Abbreviations: LOD, logarithm of odds
genotyping. The marker alleles were visualised using Genotyper software (Applied Biosystems).

**Statistical analysis**

Multipoint or two point analysis for logarithm of odds (LOD) scores was carried out on all possible weighted 170 pairs, using the MAPMAKER/SIBS or MERLIN program. Multipoint LOD scores >1.18 \((p \leq 0.01)\) were identified as nominal evidence for linkage, LOD scores >2.2 as suggestive \((p \leq 0.0007)\), and LOD scores >3.6 as significant \((p \leq 0.00002)\).

For a chromosomal locus showing the highest multipoint LOD score, simulation studies were carried out to evaluate a genome-wide significance of linkage using the MERLIN program which generates simulated chromosomes conditional on family structure, actual marker spacings, and allele frequencies, as well as missing data patterns.

**Subgroups stratification**

Since numerous reports indicate different etiologies in subsites or histological subtypes, linkage analyses were carried out for subgroups stratified on tumour localisation and histology. As it can be assumed that a sibpair shares the same genetic factors involved in gastric cancer, subgroups included sibpairs where at least one sib met the criteria. Tumour localisation was classified according to the rules of the Japanese Gastric Cancer Association with cancer developing in the upper third of the stomach designated as proximal gastric cancer and the rest as distal. Age at diagnosis (younger than 50 years) was also considered for subgroup stratification. Of the 170 affected sibpairs, 25 and 108 were classified into the proximal and distal subgroups, respectively, 11 were included in both subgroups, one did not met the criteria, and clear information of tumour localisation was not obtained for 47 sibpairs.
Regarding histological type, 76 and 62 sibpairs were classified into diffuse and intestinal subgroups, respectively, 32 were included in both subgroups, and clear histological information was not obtained for 64 sibpairs. A total of 53 sibpairs met the criteria that at diagnosis at least one sib was less than 50 years old.

RESULTS AND DISCUSSION

The entire set of 170 informative affected sibpairs with gastric cancer was initially analysed. Figure 1 shows the multipoint LOD scores for gastric cancer as a qualitative trait with markers on all chromosomes, determined using the MAPMAKER/SIBS program. Four chromosomal regions, 1p32, 2q33–2q35, 11p13–14, and 21q21, were identified as providing nominal evidence for linkage with multipoint LOD scores of >1.18, corresponding to \( p < 0.01 \). The highest multipoint LOD score was observed on chromosome 2q33 and 11p14 (both D2S325 and D11S904 showed an LOD of 1.74, \( p = 0.002 \)). Two point analysis revealed an additional chromosomal region, 1q32, with an LOD score of >1.18 (D1S425, LOD = 2.16). D2S325, D11S904, and D21S1256 had LOD scores of >1.18 in multipoint and two point analyses. The two point LOD score of D2S325 was higher than that of D11S904 (1.98 and 1.37, respectively). None of the regions, however, reached the threshold for suggestive (LOD = 2.2, \( p = 0.0007 \)) or significant (LOD = 3.6, \( p = 0.00002 \)) evidence for linkage.

Gastric cancer has been classified into two subgroups based on tumour localisation (cardia or non-cardia) and into two histological subtypes (intestinal or diffuse). Most gastric cancer develops in the distal portion of the stomach (non-cardia) and a spontaneous decrease in the incidence of this type has been observed in many populations, whereas the incidence of cancer originating in the gastric cardia appears to be relatively stable. The intestinal type seems to be highly prevalent in populations with high rates of gastric cancer. By contrast, the diffuse type is predominant in populations with a low incidence of the disease. These diverging trends in incidence imply different etiologies in both subsites and histological subtypes of gastric cancer. In order to examine if the weak linkage of gastric cancer with the chromosomal regions observed in the entire data set shows subsite or histological subtype specificity, linkage analyses were carried out for stratified subgroups.

### Table 1

<table>
<thead>
<tr>
<th>Marker name</th>
<th>Cytogenic position (cM)*</th>
<th>Marker position*</th>
<th>Heterozygosity (%)</th>
<th>Multipoint data†</th>
<th>Two point data†</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>LOD</td>
<td>Point wise p</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>p</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>LOD</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proximal, n = 25†</td>
<td>Chromosome 1</td>
<td>D1S2797</td>
<td>77.6</td>
<td>1p33</td>
<td>73.8</td>
</tr>
<tr>
<td></td>
<td></td>
<td>D1S2890</td>
<td>87.7</td>
<td>1p32.2</td>
<td>76.9</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chromosome 2</td>
<td>D2S364</td>
<td>186.2</td>
<td>2q31.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>D2S117</td>
<td>194.5</td>
<td>2q32.3</td>
<td>89.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>D2S325</td>
<td>210.9</td>
<td>2q33</td>
<td>74.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>D2S2382</td>
<td>220.7</td>
<td>2q35</td>
<td>51.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>D2S126</td>
<td>220.1</td>
<td>2q36.1</td>
<td>76.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chromosome 5</td>
<td>D5S407</td>
<td>64.7</td>
<td>5q11.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>D5S647</td>
<td>74.7</td>
<td>5q23.1</td>
<td>82.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chromosome 8</td>
<td>D8S277</td>
<td>8.3</td>
<td>8p23.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chromosome 19</td>
<td>D19S884</td>
<td>26.0</td>
<td>19q13.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>D19S220</td>
<td>61.4</td>
<td>19q13.13</td>
<td>90.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chromosome X</td>
<td>DXS993</td>
<td>66.1</td>
<td>Xp11.4</td>
</tr>
<tr>
<td>Distal, n = 108</td>
<td>Chromosome 2</td>
<td>D2S162</td>
<td>20.0</td>
<td>2p25.1</td>
<td>78.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>D2S325</td>
<td>204.5</td>
<td>2q33.3</td>
<td>74.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chromosome 11</td>
<td>D11S904</td>
<td>33.6</td>
<td>11p14.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>D11S935</td>
<td>49.6</td>
<td>11p13</td>
<td>75.5</td>
</tr>
<tr>
<td>Diffuse, n = 76</td>
<td>Chromosome 11</td>
<td>D11S904</td>
<td>33.6</td>
<td>11p14.2</td>
<td>16.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>D11S935</td>
<td>45.9</td>
<td>11p13</td>
<td>75.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>D11S1314</td>
<td>73.6</td>
<td>11q13.4</td>
<td>74.6</td>
</tr>
<tr>
<td>Intestinal, n = 62</td>
<td>Chromosome 21</td>
<td>D21S1256</td>
<td>8.6</td>
<td>21q21.1</td>
<td>63.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>D21S1914</td>
<td>19.4</td>
<td>21q21.2</td>
<td>87.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chromosome 2</td>
<td>D2S325</td>
<td>204.5</td>
<td>2q33.3</td>
</tr>
<tr>
<td>Age at diagnosis, n = 53</td>
<td>Chromosome 2</td>
<td>D2S2382</td>
<td>220.7</td>
<td>2q35</td>
<td>51.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>D2S1256</td>
<td>8.6</td>
<td>21q21.1</td>
<td>63.5</td>
</tr>
</tbody>
</table>

*Marker positions are from the database of a GenethonMap in the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/).
†Entries with an LOD score of <1.18 are in parentheses.
‡Number of sibpairs analysed.
which was beyond the strict level for genome-wide statistical significance. This marker showed an LOD score of 2.93 (p = 0.0001) in a two point analysis. Simulation studies using the MERLIN program for the proximal subgroup revealed that only two replicates demonstrated multipoint LOD scores of >3.6 for D2S325 among 1000 replicates of simulation, suggesting a genetic link between the proximal subgroup and this marker. To further confirm this finding, an additional seven markers covering 50 cM of chromosome 2q31–q36 were typed and reanalysis including the initial markers on this region was carried out (fig 2). This additional mapping revealed that the LOD scores for 2q33–q35 were greater than 2.2, confirming evidence suggestive of linkage. The strongest linkage signal was obtained for D2S325 with an LOD score of 3.37. The MERLIN program, which calculates the LOD score using the Kong and Cox method under an exponential model, was applied to region 2q33–q35 for additional information. It was found that D2S325 showed a multipoint LOD score of 2.66 (p = 0.0002) (fig 2, dotted line). Thus, even though the sample size was small, 2q33–q35 was suggested to be a gastric cancer susceptibility locus, especially for tumours localised in the proximal region of the stomach. On the other hand, two chromosomal regions, 2q33 and 11p14, showed weak linkage in an analysis of the distal gastric cancer subgroup (table 1).

When histological subgroups were analysed, 11p13–14 and 21q21 showed linkage in the diffuse and intestinal subgroups, respectively (table 1). In particular, markers D11S904 and D11S935 on 11p13–p14 showed moderate linkage signals in multipoint and two point analyses in the diffuse type (multipoint LOD = 2.12 and 1.45, two point LOD = 1.57 and 3.51, respectively). The etiology of the diffuse type of gastric cancer is presumed to be less affected by environmental factors than the intestinal type. A study reporting association of the CDH1 germline mutations with the development of the diffuse type provided the first evidence that gastric cancer had a molecular basis in predisposed families. Our data suggest that genetic polymorphism in other genes on chromosome 11p13–14 may be responsible for tumourigenesis of the diffuse type of gastric cancer. We also analysed a subgroup of sibpairs with age at diagnosis younger than 50 years old. Even though the LOD scores were not high, two linkage signals were detected on chromosome 2q33–q35 and 21q21 which also showed nominal evidence for linkage in an analysis of the entire data set (table 1).

Gastric cancer is a complex disease, and there are different etiologies, including environmental and genetic factors, for the different types. Previous studies indicate that gastric cardia cancer is less influenced by H. pylori infection, the main environmental risk factor, than non-cardia cancer. As the incidence of cardia cancer is reported to be stable, it may be that hereditary components have important roles in the tumourigenesis of this type of gastric cancer. Lagergren and co-workers reported that the risk of cardia cancer was moderately increased among persons with first degree relatives with gastric cancer in a nationwide case-control study in Sweden. This finding also supports a genetic link with cardia cancer. In this present study, we found that chromosome 2q33–q35 is a potential susceptibility locus for proximal gastric cancer. Data on the genome-wide scan presented here may contribute to a better understanding of genetic factors related to gastric cancer, particularly cardia cancer, although larger samples and additional ethnic populations will be needed.

ACKNOWLEDGEMENTS
We thank all patients and family members for participating in this study, T Tokuyasu, M Sonoda, K Fukuyma, M Obo, J Nakai, S Ohyama, N Tajiri, and T Akinaga, H Yamauchi for technical services, and M Ohara for comments.

ELECTRONIC-DATABASE INFORMATION

Authors’ affiliations
M Aoki, K Sakai, K Yamamoto, Division of Molecular Population Genetics, Department of Molecular Genetics, Medical Institute of Bioregulation and COE Program on Lifestyle-Related Diseases, Kyushu University, Fukuoka, Japan
Y Yamamura, Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
H Noshiro, Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
J Yokota, T Kohno, Biology Division, National Cancer Center Research Institute, Tokyo, Japan
T Tokino, S Ishida, Department of Molecular Biology, Cancer Research Institute, School of Medicine, Sapporo Medical University, Sapporo, Japan
S Ohyama, Department of GI Surgery, Cancer Institute Hospital, Tokyo, Japan
I Ninomiya, Gastroenterologic Surgery, Department of Oncology, Division of Cancer Medicine, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan
K Uesaka, Surgical Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
M Kitajima, Department of Surgery, School of Medicine, Keio University, Tokyo, Japan
S Shimada, Second Department of Surgery, Kumamoto University School of Medicine, Kumamoto, Japan
S Matsuno, First Department of Surgery, Tohoku University School of Medicine, Sendai, Japan
M Yano, Department of Surgery and Clinical Oncology, Graduate School of Medicine, Osaka University, Osaka, Japan
M Hiratsuka, Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
H Sugimura, Department of Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan
F Itoh, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
T Minamoto, Division of Diagnostic Molecular Oncology and Surgical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan

Y Maehara, Department of Surgery and Science, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan

S Takenoshita, Second Department of Surgery, Fukushima Medical University, Fukushima, Japan

T Aikou, First Department of Surgery, Kagoshima University School of Medicine, Kagoshima, Japan

H Katai, National Cancer Center Hospital, Tokyo, Japan

K Yoshimura, Cancer Information and Epidemiology Division, National Cancer Center Research Institute, Tokyo, Japan

T Takahashi, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan

K Akagi, Saitama Cancer Center Research Institute, Saitama, Japan

M Sairenji, Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan

T Sasazuki, International Medical Center of Japan, Tokyo, Japan

This work was supported by a Grant-in-Aid for Scientific Research on Priority Areas ‘Cancer’, and a Grant from the 21st COE Program from the Ministry of Education, Culture, Sports, Science and Technology, Japan.

Competing interests: none declared

Collaborators, listed in alphabetical order, are as follows: Shuichi Hokita (Kagoshima University), Masami Ikeda (Toho University), Kohzoh Imai (Sapporo Medical University), Osamu Ishikawa (Osaka Medical Center for Cancer and Cardiovascular Diseases), Hiroshi Kobayashi (Seirei Hamamatsu Hospital), Yasuhiro Kadera (Aichi Cancer Center Hospital), Tetsuro Kubota (Keio University), Masayoshi Mai (Kumamoto Hamamatsu Hospital), Noriko Noda (Nagoya University), Tadashi Toshifusa Nakajima (Cancer Institute Hospital), Yuzo Nakaya (Seirei Hamamatsu Hospital), Noriko Noda (Nagoya University), Yasuhiro Kodera (Aichi Cancer Center Hospital), Osamu Ishikawa (Osaka Medical Center for Cancer and Cardiovascular Diseases), Morito Monden (Osaka University), Mami Mihara (National Cancer Center), Koichi Miwa (Tokyo Metropolitan Komagome Hospital, Tokyo, Japan), Tatsuhiko Morita (Oita University), Tetsuro Kubota (Keio University), Masayoshi Mai (Kumamoto Hamamatsu Hospital), Yasuhiro Kodera (Aichi Cancer Center Hospital), Osamu Ishikawa (Osaka Medical Center for Cancer and Cardiovascular Diseases), Morito Monden (Osaka University), Mami Mihara (National Cancer Center), Koichi Miwa (Tokyo Metropolitan Komagome Hospital, Tokyo, Japan)

Correspondence to: Takehiko Sasazuki, International Medical Center of Japan, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan; sasazuki@nciyiro.hosp.go.jp

Accepted for publication 2 June 2004

REFERENCES


26 Launonen P, Nevalainen TI. Epidemiology of intestinal and diffuse types of gastric cancer. A time-trend study in Finland with comparison between studies from high- and low-risk areas. Cancer 1993;71:2926–33.


www.jmedgenet.com